About inspiremd - NSPR
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.
NSPR At a Glance
InspireMD, Inc.
6303 Waterford District Drive
Miami, Florida 33126
| Phone | N/A | Revenue | 8.98M | |
| Industry | Medical Specialties | Net Income | -48,786,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 28.107% | |
| Fiscal Year-end | 12 / 2026 | Employees | 127 | |
| View SEC Filings |
NSPR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.752 |
| Price to Book Ratio | 1.404 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.307 |
| Enterprise Value to Sales | 7.081 |
| Total Debt to Enterprise Value | 0.052 |
NSPR Efficiency
| Revenue/Employee | 70,700.787 |
| Income Per Employee | -384,141.732 |
| Receivables Turnover | 3.496 |
| Total Asset Turnover | 0.155 |
NSPR Liquidity
| Current Ratio | 5.739 |
| Quick Ratio | 5.421 |
| Cash Ratio | 5.061 |
NSPR Profitability
| Gross Margin | 29.502 |
| Operating Margin | -546.965 |
| Pretax Margin | -542.633 |
| Net Margin | -543.334 |
| Return on Assets | -83.961 |
| Return on Equity | -106.885 |
| Return on Total Capital | -83.408 |
| Return on Invested Capital | -102.377 |
NSPR Capital Structure
| Total Debt to Total Equity | 5.96 |
| Total Debt to Total Capital | 5.625 |
| Total Debt to Total Assets | 4.74 |
| Long-Term Debt to Equity | 4.029 |
| Long-Term Debt to Total Capital | 3.802 |